Home » Stocks » SPPI

Spectrum Pharmaceuticals, Inc. (SPPI)

Stock Price: $4.73 USD 0.17 (3.73%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $4.70 -0.03 (-0.63%) Nov 27, 4:56 PM

Stock Price Chart

Key Info

Market Cap 690.21M
Revenue (ttm) 109.33M
Net Income (ttm) -160.26M
Shares Out 145.92M
EPS (ttm) -1.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $4.73
Previous Close $4.56
Change ($) 0.17
Change (%) 3.73%
Day's Open 4.61
Day's Range 4.57 - 4.79
Day's Volume 1,093,665
52-Week Range 1.74 - 10.57

More Stats

Market Cap 690.21M
Enterprise Value 491.90M
Earnings Date (est) Mar 10, 2021
Ex-Dividend Date n/a
Shares Outstanding 145.92M
Float 143.51M
EPS (basic) -1.36
EPS (diluted) -1.37
FCF / Share -0.97
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 12.86M
Short Ratio 5.68
Short % of Float 8.96%
Beta 2.48
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 6.31
PB Ratio 3.95
Revenue 109.33M
Operating Income -145.20M
Net Income -160.26M
Free Cash Flow -126.81M
Net Cash 198.31M
Net Cash / Share 1.36
Gross Margin n/a
Operating Margin -132.81%
Profit Margin n/a
FCF Margin -115.98%
ROA -34.11%
ROE -80.17%
ROIC -168.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (6)

Buy 4
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$10.80*
(128.33% upside)
Low
7.00
Current: $4.73
High
15.00
Target: 10.80
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue---14616318715626819374.11
Revenue Growth----9.91%-12.99%19.88%-41.78%38.73%160.36%-
Gross Profit---11113516012722115956.67
Operating Income-141-138-116-62.89-42.59-31.57-38.7980.7756.55-51.12
Net Income-113-121-92.19-69.77-52.64-45.72-62.1394.2049.93-47.06
Shares Outstanding11110385.1272.8264.8864.7160.7358.5953.2749.50
Earnings Per Share-1.02-1.17-1.08-0.96-0.81-0.71-1.021.460.86-0.95
EPS Growth-------69.77%--
Operating Cash Flow-135-62.40-38.86-40.466.74-3.63-2.0971.9643.29-22.54
Capital Expenditures-8.97-0.11-0.47-0.08-0.22-25.93-0.16-0.31-0.48-1.58
Free Cash Flow-144-62.51-39.32-40.546.52-29.56-2.2571.6542.81-24.12
Cash & Equivalents22420422815814013316014316195.67
Total Debt--38.2297.0499.3896.3091.4875.000.010.04
Net Cash / Debt22420418961.4340.6136.9568.3068.0116195.63
Assets263391487429419490499505281164
Liabilities73.0411913619320623521821688.6989.16
Book Value19027135123621325528228919274.48
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Spectrum Pharmaceuticals, Inc.
Country United States
Employees 146
CEO Joseph W. Turgeon

Stock Information

Ticker Symbol SPPI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SPPI
IPO Date September 26, 1996

Description

Spectrum Pharmaceuticals, a biopharma company, develops and commercializes oncology and hematology drug products. The company is developing ROLONTIS, a novel long-acting granulocyte colony-stimulating for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFN√°, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of relapsed or refractory non-Hodgkin's lymphoma patients, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. for interferon therapeutics drug delivery platform. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.